Economic evaluations of neuraminidase inhibitors to control influenza

References

• Nicholson KG, Kent J, Hammersley V, Cancio E. Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden. Brit. Merl 315(7115), 1060–1064 (1997).
   PubMedGoogle Scholar
• Zambon M, Hays J, Webster A, Newman R, Keene 0. Diagnosis of influenza in the community: relationship of clinical diagnosis to confirmed virological, serologic, or molecular detection of influenza. Arch. Intern. Merl 161(17), 2116–2122 (2001).
   Google Scholar
• Ellis JS, Fleming DM, Zambon MC. Multiplex reverse transcription-PCR for surveillance of influenza A and B viruses in England and Wales in 1995 and 1996. j Clin. Microbial. 35 (8), 2076–2082 (1997).
   Google Scholar
• Fleming DM, Chakraverty P, Sadler C, Litton P Combined clinical and virological surveillance of influenza in winters of 1992 and 1993–4. Brit. Med. 311(7000), 290–291 (1995).
   Google Scholar
• Monto AS, Ohmit SE, Margulies JR, Talsma A. Medical practice-based influenza surveillance: viral prevalence and assessment of morbidity. Am. J. Epidemial 141(6), 502–506 (1995).
   Google Scholar
• Carrat F, Tachet A, Rouzioux C, Housset B, Valleron AJ. Evaluation of clinical case definitions of influenza: detailed investigation of patients during the 1995–1996 epidemic in France. Gun. Infect. Dis. 28(2), 283–290 (1999).
   Google Scholar
• Monto AS, Fleming DM, Henry D et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J. Infect. Dis. 180(2), 254–261 (1999).
   Google Scholar
• Hayden FG, Osterhaus AD, Treanor JJ et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl. J. Merl 337(13), 874–880 (1997).
   Google Scholar
• MIST Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group [published errata appear in Lancet353, 504 (1999) and 353, 1104 (1999)1. Lancet 352(9144), 1877–1881 (1998).
   Google Scholar
• Treanor JJ, Hayden FG, Vrooman PS etal Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAIVIA 283(8), 1016–1024 (2000).
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Aoki FY, Osterhaus AD et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 355(9218), 1845–1850 (2000).
   PubMed Web of Science ®Google Scholar
• Boivin G, Goyette N, Hardy I, Aoki F, Wagner A, Trottier S. Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults. Infect. Dis. 181(4), 1471–1474 (2000).
   Web of Science ®Google Scholar
• Sullivan KM. Health impact of influenza in the United States. PharmacoEconomics 9\(Suppl. 3), 26–33 (1996).
   Google Scholar
• Carrat F, Sahler C, Rogez S eta]. Influenza burden of illness: estimates from a national prospective survey of household contacts in France. Arch. Intern. Merl 162(16), 1842–1848 (2002).
   Google Scholar
• Flahault A, Dias-Ferrao V, Chaberty P, Esteves K, Valleron AJ, Lavanchy D. FluNet as a tool for global monitoring of influenza on the Web. JAIVIA 280(15), 1330–1332 (1998).
   PubMed Web of Science ®Google Scholar
• Couch RB. Drug therapy: prevention and treatment of influenza. N Engl. J. Med. 343(24), 1778–1787 (2000).
   Google Scholar
• Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Wkly Rep. 49(RR-3), 1–38 (2000). Summary report which is essential reading. Available annually: www.cdc.gov/ mrnwr/indexbt.html.
   Google Scholar
• Centers for Disease Control and Prevention. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 51(RR-3), 1–31 (2002).
   Google Scholar
• Gross PA, Hermogenes AVV, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann. Intern. Merl 123(7), 518–527 (1995).
   Google Scholar
• Nicholson KG. Socioeconomics of influenza and influenza vaccination in Europe. PharmacoEconomics9\(Suppl. 3), 75–78 (1996).
   Google Scholar
• Hampson AW, Irving LB. Influenza vaccination: cost-effective health care for the older adult? J. Qual Clin. Pract. 17(1), 3–11 (1997).
   Google Scholar
• Ambrosch F, Fedson DS. Influenza vaccination in 29 countries. An update to 1997. PharmacoEconomics16\(Suppl. 1), 47–54 (1999).
   Google Scholar
• Lalezari J, Campion K, Keene 0, Silagy C. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch. Intern. Merl 161 (2), 212–217 (2001).
   Google Scholar
• Gravenstein S, Davidson HE. Current strategies for management of influenza in the elderly population. Clin. Infect. Dis. 35(6), 729–737 (2002).
   Google Scholar
• Jefferson T, Demicheli V, Deeks J, Rivetti D. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst. Rev. 2, (2000).
   Google Scholar
• Jefferson TO, Demicheli V, Deeks JJ, Rivetti D. Amantadine and rimantadine for preventing and treating influenza A in adults. Cochrane Database Syst. Rev. 2, (2000).
   Google Scholar
• Hayden FG, Gubareva LV, Monto AS eta]. Inhaled Zanamivir for the Prevention of Influenza in Families. N Engl. J. Merl 343(18), 1282–1289 (2000).
   Google Scholar
• Welliver R, Monto AS, Carewicz 0 eta] Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAIVIA 285(6), 748–754 (2001).
   Google Scholar
• Scuffham PA, West PA. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine 20(19-20), 2562–22578 (2002).
   PubMed Web of Science ®Google Scholar
• •Showcase of economic evaluation of NA inhibitors.
   Google Scholar
• Nichol KL, Lind A, Margolis KL eta] The effectiveness of vaccination against influenza in healthy, working adults. N Engl. Merl 333(14), 889–893 (1995).
   Google Scholar
• Nichol KL. Clinical effectiveness and cost effectiveness of influenza vaccination among healthy working adults. Vaccine 17 (Suppl. 1), S67—S73 (1999).
   Google Scholar
• Bridges CB, Thompson WW, Meltzer MI et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAMA 284 (13), 1655–1663 (2000).
   PubMed Web of Science ®Google Scholar
• Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch. Intern. Merl 161(5), 749–759 (2001).
   Google Scholar
• Lee PY, Matchar DB, Clements DA, Huber J, Hamilton JD, Peterson ED. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann. Intern. Merl 137(4), 225–231 (2002).
   Google Scholar
• •Showcase of economic evaluation of NA inhibitors.
   Google Scholar
• Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet 355(9206), 827–835 (2000).
   PubMed Web of Science ®Google Scholar
• Bantia S, Parker CD, Ananth SL, et al. Comparison of the anti-influenza virus activity of RVVJ-270201 with those of oseltamivir and zanamivir. Antimicrob. Agents. Chemother. 45(4), 1162–1167 (2001).
   Google Scholar
• Govorkova EA, Leneva IA, Goloubeva OG, Bush K, Webster RG. Comparison of efficacies of RVVJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob. Agents Chemother. 45(10), 2723–2732 (2001).
   Google Scholar
• Gubareva LV, Webster RG, Hayden FG. Comparison of the activities of zanamivir, oseltamivir, and RVVJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob. Agents Chemother. 45 (12), 3403–3408 (2001).
   Google Scholar
• Boivin G, Goyette N. Susceptibility of recentCanadian influenza A and B virus isolates to different neuraminidase inhibitors. Antiviral Res. 54(3), 143–147 (2002).
   Google Scholar
• Burls A, Clark W Stewart T eta]. Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation. Health Technol Assess. 6(9), 1–87. (2002).
   Google Scholar
• •Showcase of economic evaluation of NA inhibitors.
   Google Scholar
• Hayden FG, Treanor JJ, Fritz RS etal. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAIVIA 282(13), 1240–1246 (1999).
   PubMed Web of Science ®Google Scholar
• Williamson JC, Pegram PS. Respiratory distress associated with zanamivir. N Engl J. Merl 342(9), 661–662 (2000).
   Google Scholar
• Diggory P, Fernandez C, Humphrey A, Jones V, Murphy M. Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. Brit. Merl J. 322(7286), 577–579 (2001).
   Google Scholar
• Gubareva LV, Webster RG, Hayden FG. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral. Res. 53(1), 47-61(2002).
   Google Scholar
• SaSSi F, Archard ML, McDaid D. Searching literature databases for health care economic evaluations: how systematic can we afford to be? Merl Care 40(5), 387–394 (2002).
   Google Scholar
• Mauskopf JA, Cates SC, Griffin AD, Neighbors DM, Lamb SC, Rutherford C. Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia. PharmacoEconomics 17 (6), 611–620 (2000).
   PubMed Web of Science ®Google Scholar
• •Showcase of economic evaluation of NA inhibitors.
   Google Scholar
• Brady B, McAuley L, Shukla VK. Economic evaluation of zanamivir for the treatment of influenza. Report No.13. Canadian Coordinating Office for Health Technology Assessment, Canada (2001).
   Google Scholar
• •Showcase of economic evaluation of NA inhibitors.
   Google Scholar
• Muennig PA, Khan K. Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults. Clin. Infect. Dis. 33(11), 1879–1885 (2001).
   Google Scholar
• •Showcase of economic evaluation of NA inhibitors.
   Google Scholar
• Smith KJ, Roberts MS. Cost-effectiveness of newer treatment strategies for influenza. AinJ Merl 113(4), 300–307 (2002).
   PubMed Web of Science ®Google Scholar
• •Showcase of economic evaluation of NA inhibitors.
   Google Scholar
• Schwarzinger M, Housset B, Carrat E Rapid flu test and neuraminidase inhibitors in healthy adults : a cost-benefit analysis. In: ptions for the control of influenza IV ADME Osterhaus eta] (Ed.), Elsevier Science B.V., Hersonissos, Greece, (2000).•
   Google Scholar
• •Showcase of economic evaluation of NA inhibitors.
   Google Scholar
• Schwarzinger M. Analyse cola-benefice des inhibiteurs des neuraminidases et des tests diagnostiques rapides de la grippe dans la population active des Etats-Unis d'Amérique et de France. These de Doctorat en Médecine. Université Paris France 6, (2001).
   Google Scholar
• •Showcase of economic evaluation of NA inhibitors.
   Google Scholar
• Blitz SG, Cram P, Chernew ME, Monto AS, Fendrick AM. Diagnostic testing or empirical neuraminidase inhibitor therapy for patients with influenza-like illness: what a difference a day makes. Am. J. Manag. Care 8(3), 221–227 (2002).
   Google Scholar
• •Showcase of economic evaluation of NA inhibitors.
   Google Scholar
• Kaiser L, Keene ON, Hammond JM, Elliott M, Hayden FG. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch. Intern. Med 160(21), 3234–3240 (2000).
   Google Scholar
• Aoki FY, Fleming DM, Griffin AD, Lacey LA, Edmundson S. Impact of zanamivir treatment on productivity, health status and healthcare resource use in patients with influenza. Zanamivir Study Group. PharmacoEconomirs 17(2), 187–195 (2000).
   Google Scholar
• Drummond M, O'Brien B, Stoddart G, Torrance G. Methods for the Economic Evaluation of Health Care Programmes. 2nd Edition. Oxford University Press, Oxford, UK (1997).
   Google Scholar
• ••Essential reading, very well-developed texton the willingness-to-pay approach.
   Google Scholar
• Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. Oxford University Press, NY, USA (1996).
   Google Scholar
• Brouwer WB, Koopmanschap MA, Rutten FE Productivity losses without absence: measurement validation and empirical evidence. Health Policy 48W, 13–27 (1999).
   Google Scholar
• Monto AS, Gravenstein S, Elliott M, Colopy M, Schweinle J. Clinical signs and symptoms predicting influenza infection. Arch. Intern. Med 161,1351–1352 (2000).
   Google Scholar
• Neuzil KM, Reed GVV, Mitchel EF Jr, Griffin MR. Influenza-associated morbidity and mortality in young and middle-aged women. JAIVIA 281(10), 901–907 (1999).
   PubMed Web of Science ®Google Scholar
• Jansen SJ, Stiggelbout AM, Wakker PP et al Patients' utilities for cancer treatments: a study of the chained procedure for the standard gamble and time tradeoff. Med. Decis. Making 18 (4), 391–399 (1998).
   Google Scholar
• Hawthorne G, Richardson J. Measuring the value of program outcomes: a review of multiattribute utility measures. Expert Rev Pharmacoeconomics Outcomes Res. 1(2), 215–228 (2001).
   Google Scholar
• Birch S, Gafni A, O'Brien B. Willingness to pay and the valuation of programmes for the prevention and control of influenza. PharmacoEconomics 16 (Suppl. 1), 55–61 (1999).
   Google Scholar
• Carrat F, Sahler C, Le Gales C, Schwarzinger M, Nicolas M, Bungener M, on behalf of the EPIGRIPPE group. How much are patients willing to pay for an earlier alleviation of influenza? In: Options for the control of Influenza IV International Congress Series 1219. Elsevier 67–71,2001
   Google Scholar
• Meier CR, Napalkov PN, Wegmuller Y, Jefferson T, Jick H. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. Eur j Clin. Mcrobiol Infect. Dis. 19(11), 834–842 (2000).
   Google Scholar
• Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAIVIA 278(11), 901–904 (1997).
   PubMed Web of Science ®Google Scholar
• Neu HC. The crisis in antibiotic resistance. Science 257(5073), 1064–1073 (1992).
   PubMed Web of Science ®Google Scholar
• Cohen ML. Epidemiology of drug resistance: implications for a post-antimicrobial era. Science 257(5073), 1050–1055 (1992).
   PubMed Web of Science ®Google Scholar
• Gonzales R, Bartlett JG, Besser RE et al Principles of appropriate antibiotic use for treatment of acute respiratory tract infections in adults: background, specific aims, and methods. Ann. Intern Med 134(6), 479–486 (2001).
   PubMed Web of Science ®Google Scholar
• Gonzales R, Bartlett JG, Besser RE, Hickner JM, Hoffman JR, Sande MA. Principles of appropriate antibiotic use for treatment of nonspecific upper respiratory tract infections in adults: background. Ann. Intern Med 134(6), 490–494 (2001).
   PubMed Web of Science ®Google Scholar
• Coast J, Smith RD, Millar MR. Superbugs: should antimicrobial resistance be included as a cost in economic evaluation? Health Econ. 5 (3), 217–226 (1996).
   Google Scholar
• Coast J, Smith R, Karcher AM, Wilton P, Millar M. Superbugs II: how should economic evaluation be conducted for interventions which aim to contain antimicrobial resistance? Health Econ. 11(7), 637–647 (2002).
   Google Scholar
• Chapman GB, Coups EJ. Predictors of influenza vaccine acceptance among healthy adults. Prey. Med. 29(4), 249–262 (1999).
   PubMed Web of Science ®Google Scholar
• Stone EG, Morton SC, Hulscher ME eta]. Interventions that increase use of adult immunization and cancer screening services: a meta-analysis. Ann. Intern. Med. 136(9), 641–651 (2002).
   Google Scholar
• Brass ER Changing the status of drugs from prescription to over-the-counter availability. N. Engl Med 345(11), 810–816 (2001).
   PubMedGoogle Scholar
• Sackett DL, Torance GW. The utility of different health states as perceived by the general public.J Chronic Dis. 31(11), 697–704 (1978).
   Google Scholar